Potential for pharmacokinetic interactions between ambrisentan and cyclosporine

Clinical Pharmacology and Therapeutics

Volumn 88, Issue 4, 2010, Pages 513-520

  Spence, R ^a   Mandagere, A ^a   Richards, D B ^b   Magee, M H ^c   Dufton, C ^a   Boinpally, R R ^a  

^a GILEAD SCIENCES   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

^c GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYMETHYLAMBRISENTAN; AMBRISENTAN; CYCLOSPORIN A; DRUG METABOLITE; UNCLASSIFIED DRUG; ANTIHYPERTENSIVE AGENT; CYCLOSPORIN; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST; IMMUNOSUPPRESSIVE AGENT; MULTIDRUG RESISTANCE PROTEIN; ORGANIC ANION TRANSPORTER; PHENYLPROPIONIC ACID DERIVATIVE; PYRIDAZINE DERIVATIVE;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE; CONSTIPATION; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG INDUCED HEADACHE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FLUSHING; HOT FLUSH; HUMAN; HUMAN EXPERIMENT; LIMB PAIN; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; NOSE CONGESTION; PARESTHESIA; PHARYNX HEMORRHAGE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SIDE EFFECT; VOMITING; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DRUG INTERACTION;

ADULT; ANTIHYPERTENSIVE AGENTS; AREA UNDER CURVE; CYCLOSPORINE; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; ORGANIC ANION TRANSPORTERS; P-GLYCOPROTEIN; PHENYLPROPIONATES; PYRIDAZINES; RECEPTORS, ENDOTHELIN; CYTOCHROME P-450 CYP3A INHIBITORS; ENDOTHELIN RECEPTOR ANTAGONISTS;

EID: 77957020310     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.120     Document Type: Article

References (24)

1. Horn, E.M., Widlitz, A.C. & Barst, R.J. Sitaxsentan, a selective endothelin-A receptor antagonist for the treatment of pulmonary arterial hypertension. Expert Opin. Investig. Drugs 13, 1483-1492 (2004).
2. Actelion Pharmaceuticals Ltd. Tracleer (bosentan) tablets. United States Food and Drug Administration Drug Product Label (2009).
3. Pfizer Canada Inc. Thelin (sitaxsentan sodium) Product Monograph. 4 November 2008.
4. Gilead Sciences I. Letairis (ambrisentan) tablets for oral use. United States Food and Drug Administration Drug Product Label (2009).
5. Gilead Sciences Inc. Food and Drug Administration [Clinical Pharmacology & Biopharmaceutics Review (Part 2)] for original New Drug Application 22-081 http://www.accessdata.fda.gov/drugsatfda-docs/nda/2007/022081s000-ClinPharmR- P2.pdf (2007).
6. Gilead Sciences I. Food and Drug Administration [Clinical Pharmacology & Biopharmaceutics Review (part 1)] for original New Drug Application 22-081 (2007).
7. Spence, R., Mandagere, A., Dufton, C. & Venitz, J. Pharmacokinetics and safety of ambrisentan in combination with sildenafil in healthy volunteers. J. Clin. Pharmacol. 48, 1451-1459 (2008).
8. Spence, R., Mandagere, A., Harrison, B., Dufton, C. & Boinpally, R. No clinically relevant pharmacokinetic and safety interactions of ambrisentan in combination with tadalafil in healthy volunteers. J. Pharm. Sci. 98, 4962-4974 (2009).
9. Walker, G., Mandagere, A., Dufton, C. & Venitz, J. The pharmacokinetics and pharmacodynamics of warfarin in combination with ambrisentan in healthy volunteers. Br. J. Clin. Pharmacol. 67, 527-534 (2009).
10. Brouwer, K.R., Wille, K.R. & Gorczynski, R.J. Ambrisentan, darusentan, bosentan, and sitaxsentan: differences in inhibition of hepatobilliary transporters in two species. Drug Metab. Rev. 2007; 39:A296.
11. Richards, D.B., Walker, G.A., Mandagere, A., Magee, M.H. & Henderson, L.S. Effect of ketoconazole on the pharmacokinetic profile of ambrisentan. J. Clin. Pharmacol. 49, 719-724 (2009).
12. Harrison, B. et al. No clinically relevant effect of rifampin on the pharmacokinetics and safety of ambrisentan in healthy volunteers. Clin. Drug Investig, in press.
13. Kon, V., Sugiura, M., Inagami, T., Harvie, B.R., Ichikawa, I. & Hoover, R.L. Role of endothelin in cyclosporine-induced glomerular dysfunction. Kidney Int. 37, 1487-1491 (1990).
14. Perico, N., Dadan, J. & Remuzzi, G. Endothelin mediates the renal vasoconstriction induced by cyclosporine in the rat. J. Am. Soc. Nephrol. 1, 76-83 (1990).
15. Fogo, A., Hellings, S.E., Inagami, T. & Kon, V. Endothelin receptor antagonism is protective in in vivo acute cyclosporine toxicity. Kidney Int. 42, 770-774 (1992).
16. European Medicines Agency. European Public Assessment Report for Thelin (2006).
17. Saeki, T., Ueda, K., Tanigawara, Y., Hori, R. & Komano, T. Human P-glycoprotein transports cyclosporin A and FK506. J. Biol. Chem. 268, 6077-6080 (1993).
18. Novartis. Neoral (cyclosporine). US Food and Drug Administration Drug Product Label (2009).
19. Binet, I., Wallnofer, A., Weber, C., Jones, R. & Thiel, G. Renal hemodynamics and pharmacokinetics of bosentan with and without cyclosporine A. Kidney Int. 57, 224-231 (2000).
20. T reiber, A., Schneiter, R., Delahaye, S. & Clozel, M. Inhibition of organic anion transporting polypeptide-mediated hepatic uptake is the major determinant in the pharmacokinetic interaction between bosentan and cyclosporin A in the rat. J. Pharmacol. Exp. Ther. 308, 1121-1129 (2004).
21. C ummins, C.L., Wu, C.Y. & Benet, L.Z. Sex-related differences in the clearance of cytochrome P450 3A4 substrates may be caused by P-glycoprotein. Clin. Pharmacol. Ther. 72, 474-489 (2002).
22. Paine, M.F., Ludington, S.S., Chen, M.L., Stewart, P.W., Huang, S.M. & Watkins, P.B. Do men and women differ in proximal small intestinal CYP3A or P-glycoprotein expression? Drug Metab. Dispos. 33, 426-433 (2005).
23. Wolbold, R. et al. Sex is a major determinant of CYP3A4 expression in human liver. Hepatology 38, 978-988 (2003).
24. FDA. Guidance for Industry Bioavailability and Bioequivalence Studies for Orally Administered Drug Products-General Considerations (2003).